Patents by Inventor Nikoo Falahatpisheh

Nikoo Falahatpisheh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 1H-PYRROLO[2,3-c]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-c]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS
    Publication number: 20250145621
    Abstract: The present invention relates to substituted pyrrolopyridinones and substituted pyrazolopyridinones which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
    Type: Application
    Filed: January 10, 2025
    Publication date: May 8, 2025
    Inventors: Andrew P. Combs, Thomas P. Maduskuie, JR., Nikoo Falahatpisheh
  • 1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c] pyridin-7(6H)-ones as inhibitors of BET proteins
    Patent number: 12227502
    Abstract: The present invention relates to substituted pyrrolopyridinones and substituted pyrazolopyridinones which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: May 31, 2023
    Date of Patent: February 18, 2025
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Andrew P. Combs, Thomas P. Maduskuie, Jr., Nikoo Falahatpisheh
  • AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
    Publication number: 20240400541
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Application
    Filed: February 1, 2024
    Publication date: December 5, 2024
    Inventors: Stacey Shepard, Andrew P. Combs, Nikoo Falahatpisheh, Lixin Shao
  • TERTIARY ALCOHOLS AS PI3K-y INHIBITORS
    Publication number: 20240228498
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Application
    Filed: February 1, 2024
    Publication date: July 11, 2024
    Inventors: Brent Douty, Andrew W. Buesking, David M. Burns, Andrew P. Combs, Nikoo Falahatpisheh, Ravi Kumar Jalluri, Daniel Levy, Padmaja Polam, Lixin Shao, Stacey Shepard, Artem Shvartsbart, Richard B. Sparks, Eddy W. Yue
  • Substituted imidazo[2,1-f][1,2,4]triazines as PI3K-gamma inhibitors
    Patent number: 12030885
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Grant
    Filed: February 23, 2021
    Date of Patent: July 9, 2024
    Assignee: Incyte Corporation
    Inventors: Andrew W. Buesking, Richard B. Sparks, Andrew P. Combs, Brent Douty, Nikoo Falahatpisheh, Lixin Shao, Stacey Shepard, Eddy W. Yue, Artem Shvartsbart, David M. Burns, Daniel Levy
  • Heterocyclic derivatives as PI3K inhibitors
    Patent number: 12006320
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Grant
    Filed: June 24, 2021
    Date of Patent: June 11, 2024
    Assignee: Incyte Corporation
    Inventors: Stacey Shepard, Yanran Ai, Andrew P. Combs, Nikoo Falahatpisheh, Lixin Shao, Artem Shvartsbart
  • Spirocyclic lactams as JAK2 V617F inhibitors
    Patent number: 11958861
    Abstract: The present application provides spirocyclic lactam compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
    Type: Grant
    Filed: February 24, 2022
    Date of Patent: April 16, 2024
    Assignee: Incyte Corporation
    Inventors: Stacey Shepard, Charles Cole, Nikoo Falahatpisheh, Kai Liu, Lixin Shao, Darius Vrubliauskas, Liangxing Wu, Wenqing Yao, Eddy W. Yue
  • Pyridine and pyridimine compounds as PI3K-gamma inhibitors
    Patent number: 11952367
    Abstract: The present disclosure provides compounds of Formula I, or pharmaceutically acceptable salts thereof, that modulate the activity of phosphoinositide 3-kinases-gamma (PI3K?) and are useful in the treatment of diseases related to the activity of PI3K? including, for example, autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Grant
    Filed: March 25, 2022
    Date of Patent: April 9, 2024
    Assignee: Incyte Corporation
    Inventors: Richard B. Sparks, Stacey Shepard, Andrew P. Combs, Andrew W. Buesking, Lixin Shao, Haisheng Wang, Nikoo Falahatpisheh
  • Tertiary alcohols as PI3K-? inhibitors
    Patent number: 11926630
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Grant
    Filed: November 30, 2021
    Date of Patent: March 12, 2024
    Assignee: Incyte Corporation
    Inventors: Brent Douty, Andrew W. Buesking, David M. Burns, Andrew P. Combs, Nikoo Falahatpisheh, Ravi Kumar Jalluri, Daniel Levy, Padmaja Polam, Lixin Shao, Stacey Shepard, Artem Shvartsbart, Richard B. Sparks, Eddy W. Yue
  • Aminopyrazine diol compounds as PI3K-? inhibitors
    Patent number: 11926616
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Grant
    Filed: December 2, 2021
    Date of Patent: March 12, 2024
    Assignee: Incyte Corporation
    Inventors: Stacey Shepard, Andrew P. Combs, Nikoo Falahatpisheh, Lixin Shao
  • 1H-PYRROLO[2,3-c]PYRIDIN-7(6H)-ONES AND PYRAZOLO[3,4-c]PYRIDIN-7(6H)-ONES AS INHIBITORS OF BET PROTEINS
    Publication number: 20240002381
    Abstract: The present invention relates to substituted pyrrolopyridinones and substituted pyrazolopyridinones which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
    Type: Application
    Filed: May 31, 2023
    Publication date: January 4, 2024
    Inventors: Andrew P. Combs, Thomas P. Maduskuie, JR., Nikoo Falahatpisheh
  • Heterocyclic compounds as PI3K-? inhibitors
    Patent number: 11773102
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Grant
    Filed: June 24, 2021
    Date of Patent: October 3, 2023
    Assignee: Incyte Corporation
    Inventors: Artem Shvartsbart, Stacey Shepard, Andrew P. Combs, Lixin Shao, Nikoo Falahatpisheh, Ge Zou, Andrew W. Buesking, Richard B. Sparks, Eddy W. Yue, Ravi Kumar Jalluri
  • 1H-pyrrolo[2,3-c]pyridin-7(6H)-ones and pyrazolo[3,4-c]pyridin-7(6H)-ones as inhibitors of BET proteins
    Patent number: 11702416
    Abstract: The present invention relates to substituted pyrrolopyridinones and substituted pyrazolopyridinones which are inhibitors of BET proteins such as BRD2, BRD3, BRD4, and BRD-t and are useful in the treatment of diseases such as cancer.
    Type: Grant
    Filed: June 4, 2021
    Date of Patent: July 18, 2023
    Assignees: Incyte Corporation, Incyte Holdings Corporation
    Inventors: Andrew P. Combs, Thomas P. Maduskuie, Jr., Nikoo Falahatpisheh
  • HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS
    Publication number: 20230009843
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Application
    Filed: June 24, 2021
    Publication date: January 12, 2023
    Inventors: Artem Shvartsbart, Stacey Shepard, Andrew P. Combs, Lixin Shao, Nikoo Falahatpisheh, Ge Zou, Andrew W. Buesking, Richard B. Sparks, Eddy W. Yue, Ravi Kumar Jalluri
  • AMINOPYRAZINE DERIVATIVES AS PI3K-y INHIBITORS
    Publication number: 20220411383
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Application
    Filed: May 24, 2021
    Publication date: December 29, 2022
    Inventors: Brent Douty, Yanran Ai, David M. Burns, Andrew P. Combs, Nikoo Falahatpisheh, Daniel Levy, Padmaja Polam, Lixin Shao, Stacey Shepard, Artem Shvartsbart, Eddy W. Yue, Andrew W. Buesking
  • SPIROCYCLIC LACTAMS AS JAK2 V617F INHIBITORS
    Publication number: 20220281887
    Abstract: The present application provides spirocyclic lactam compounds that modulate the activity of the V617F variant of JAK2, which are useful in the treatment of various diseases, including cancer.
    Type: Application
    Filed: February 24, 2022
    Publication date: September 8, 2022
    Inventors: Stacey Shepard, Charles Cole, Nikoo Falahatpisheh, Kai Liu, Lixin Shao, Darius Vrubliauskas, Liangxing Wu, Wenqing Yao, Eddy W. Yue
  • HETEROCYCLIC COMPOUNDS AS PI3K-y INHIBITORS
    Publication number: 20220251087
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts or stereoisomers thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Application
    Filed: February 23, 2021
    Publication date: August 11, 2022
    Inventors: Andrew W. Buesking, Richard B. Sparks, Andrew P. Combs, Brent Douty, Nikoo Falahatpisheh, Lixin Shao, Stacey Shepard, Eddy W. Yue, Artem Shvartsbart, David M. Burns, Daniel Levy
  • PYRIDINE AND PYRIDIMINE COMPOUNDS AS PI3K-GAMMA INHIBITORS
    Publication number: 20220227736
    Abstract: The present disclosure provides compounds of Formula I, or pharmaceutically acceptable salts thereof, that modulate the activity of phosphoinositide 3-kinases-gamma (PI3K?) and are useful in the treatment of diseases related to the activity of PI3K? including, for example, autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Application
    Filed: March 25, 2022
    Publication date: July 21, 2022
    Inventors: Richard B. Sparks, Stacey Shepard, Andrew P. Combs, Andrew W. Buesking, Lixin Shao, Haisheng Wang, Nikoo Falahatpisheh
  • TERTIARY ALCOHOLS AS PI3K-y INHIBITORS
    Publication number: 20220213107
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Application
    Filed: November 30, 2021
    Publication date: July 7, 2022
    Inventors: Brent Douty, Andrew W. Buesking, David M. Burns, Andrew P. Combs, Nikoo Falahatpisheh, Ravi Kumar Jalluri, Daniel Levy, Padmaja Polam, Lixin Shao, Stacey Shepard, Artem Shvartsbart, Richard B. Sparks, Eddy W. Yue
  • AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
    Publication number: 20220213065
    Abstract: This application relates to compounds of Formula (I): or pharmaceutically acceptable salts thereof, which are inhibitors of PI3K-? which are useful for the treatment of disorders such as autoimmune diseases, cancer, cardiovascular diseases, and neurodegenerative diseases.
    Type: Application
    Filed: December 2, 2021
    Publication date: July 7, 2022
    Inventors: Stacey Shepard, Andrew P. Combs, Nikoo Falahatpisheh, Lixin Shao